UGT1A1 plays a critical role in the metabolism of chemotherapeutic agents, influencing their efficacy and toxicity. Irinotecan, a drug used in cancer treatment, is converted to its active metabolite SN-38, which is subsequently inactivated by UGT1A1. Variations in UGT1A1 activity can lead to differences in SN-38 exposure, impacting treatment outcomes and side effect profiles. Testing for UGT1A1 polymorphisms can guide dose adjustments to optimize treatment efficacy and minimize toxicity.
